Weihai Baihe Biology Technological Co., Ltd. (SHA:603102)
China · Delayed Price · Currency is CNY 41.57
+0.32 (0.78%)
At close: May 8, 2026
SHA:603102 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 948.37 | 903.42 | 795.58 | 864.25 | 719.31 | 655.33 |
Other Revenue | 7.51 | 7.51 | 5.82 | 7 | 6.01 | 6.55 |
| 955.88 | 910.93 | 801.4 | 871.25 | 725.33 | 661.87 | |
Revenue Growth (YoY) | 16.60% | 13.67% | -8.02% | 20.12% | 9.59% | 14.45% |
Cost of Revenue | 623.32 | 598.54 | 512.02 | 550.89 | 466.93 | 390.4 |
Gross Profit | 332.56 | 312.39 | 289.38 | 320.36 | 258.4 | 271.48 |
Selling, General & Admin | 151.37 | 138.78 | 115.44 | 118.97 | 92.48 | 87.42 |
Research & Development | 36.41 | 35.89 | 35.78 | 30.95 | 22.51 | 24.06 |
Other Operating Expenses | -2.22 | -2.57 | -7.07 | -0.56 | 5.1 | 5.09 |
Operating Expenses | 188.85 | 172.39 | 145.42 | 149.49 | 120.19 | 117.51 |
Operating Income | 143.71 | 140 | 143.97 | 170.87 | 138.21 | 153.96 |
Interest Expense | -0.44 | -0.31 | -0.08 | -0.1 | -0.13 | -0.15 |
Interest & Investment Income | 12.58 | 14.41 | 14.75 | 15.5 | 8.91 | 1.71 |
Currency Exchange Gain (Loss) | -2.77 | -2.77 | 1.31 | 0.85 | 6.75 | -1.16 |
Other Non Operating Income (Expenses) | -2.12 | -0.31 | -0.2 | 0.09 | -0.37 | -0.2 |
EBT Excluding Unusual Items | 150.95 | 151.01 | 159.75 | 187.21 | 153.37 | 154.17 |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | 0.13 | 0.06 | 0.27 | -0 |
Asset Writedown | -2.06 | - | - | -0.34 | -0.04 | -0.65 |
Other Unusual Items | 1.24 | 1.47 | 1 | 6.49 | 4.63 | 15.81 |
Pretax Income | 150.11 | 152.46 | 160.88 | 193.42 | 158.22 | 169.33 |
Income Tax Expense | 19.33 | 18.47 | 21.57 | 24.36 | 20.38 | 21.29 |
Earnings From Continuing Operations | 130.78 | 133.99 | 139.31 | 169.07 | 137.84 | 148.04 |
Minority Interest in Earnings | -8.65 | -5.56 | - | - | - | - |
Net Income | 122.13 | 128.43 | 139.31 | 169.07 | 137.84 | 148.04 |
Net Income to Common | 122.13 | 128.43 | 139.31 | 169.07 | 137.84 | 148.04 |
Net Income Growth | -12.55% | -7.81% | -17.60% | 22.65% | -6.89% | 16.46% |
Shares Outstanding (Basic) | 62 | 63 | 64 | 64 | 63 | 48 |
Shares Outstanding (Diluted) | 62 | 63 | 64 | 64 | 63 | 48 |
Shares Change (YoY) | -2.22% | -1.96% | -0.21% | 2.21% | 30.36% | 0.20% |
EPS (Basic) | 1.96 | 2.05 | 2.18 | 2.64 | 2.20 | 3.08 |
EPS (Diluted) | 1.96 | 2.05 | 2.18 | 2.64 | 2.20 | 3.08 |
EPS Growth | -10.57% | -5.96% | -17.42% | 20.00% | -28.57% | 16.23% |
Free Cash Flow | 98.75 | 130.36 | 32.73 | 97.33 | 101.36 | 44.6 |
Free Cash Flow Per Share | 1.58 | 2.08 | 0.51 | 1.52 | 1.62 | 0.93 |
Dividend Per Share | 0.750 | 0.750 | 0.750 | 0.750 | 0.600 | 0.500 |
Dividend Growth | - | - | - | 25.00% | 20.00% | - |
Gross Margin | 34.79% | 34.29% | 36.11% | 36.77% | 35.63% | 41.02% |
Operating Margin | 15.03% | 15.37% | 17.96% | 19.61% | 19.05% | 23.26% |
Profit Margin | 12.78% | 14.10% | 17.38% | 19.41% | 19.00% | 22.37% |
Free Cash Flow Margin | 10.33% | 14.31% | 4.08% | 11.17% | 13.98% | 6.74% |
EBITDA | 187.74 | 183.19 | 183.8 | 207.23 | 170.16 | 176.67 |
EBITDA Margin | 19.64% | 20.11% | 22.93% | 23.79% | 23.46% | 26.69% |
D&A For EBITDA | 44.03 | 43.19 | 39.83 | 36.36 | 31.95 | 22.71 |
EBIT | 143.71 | 140 | 143.97 | 170.87 | 138.21 | 153.96 |
EBIT Margin | 15.03% | 15.37% | 17.96% | 19.61% | 19.05% | 23.26% |
Effective Tax Rate | 12.88% | 12.12% | 13.41% | 12.59% | 12.88% | 12.57% |
Revenue as Reported | 955.88 | 910.93 | 801.4 | 871.25 | 725.33 | 661.87 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.